logo
Share SHARE
FONT-SIZE Plus   Neg

MorphoSys Reports First Results From Phase 1 Study With Lanthipeptide MOR107

MorphoSys AG (MPSYY.PK) announced the completion of the first part of a phase 1 clinical study in healthy volunteers with the investigational drug candidate MOR107 ahead of schedule.

MOR107 is a selective agonist of the angiotensin II receptor type 2 (AT2-R), and is a lanthipeptide based on the proprietary technology platform of MorphoSys's subsidiary Lanthio Pharma. MOR107 is also the first lanthipeptide in MorphoSys's clinical pipeline.

Based on an initial analysis of subjects enrolled to date, in all doses tested in this first-in-human trial, based on blinded data, there were no clinically relevant safety events seen, and all adverse events observed thus far were mild and transient in nature. Moreover a dose-dependent pharmacokinetic profile for MOR107 was observed.

The study has been conducted by MorphoSys's fully owned subsidiary Lanthio Pharma B.V., Groningen, Netherlands.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Toyota is working on developing an electric car with a fast charging battery, the Chunichi Shimbun reported on Tuesday. Travelers leaving Comic-Con International in San Diego last weekend were in for a rude shock after United Airlines said that comic books were banned in their checked luggage. United Airlines claimed it was a Transportation Security Administration or TSA-mandated rule for all airlines operating out of San Diego over this weekend. A Singapore-based startup wants to make cryptocurrencies like Bitcoin go mainstream and be available for everyday transactions. TenX has built an app that serves as a digital wallet connected to the Visa card. The debit card will instantly convert multiple digital currencies into fiat money such as the dollars, yen and euros.
comments powered by Disqus
Follow RTT